Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team.

Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.

2.

Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection.

Mitchell CD, Chernoff MC, Seage GR 3rd, Purswani MU, Spiegel HM, Zilleruelo G, Abitbol C, Heckman B, Ponce CB, Oleske JM; IMPAACT 219/219C Study Team.

Pediatr Nephrol. 2015 Jan;30(1):153-65. doi: 10.1007/s00467-014-2909-1. Epub 2014 Aug 24.

3.

The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1.

Patel K, Van Dyke RB, Mittleman MA, Colan SD, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219219C Study Team.

AIDS. 2012 Oct 23;26(16):2027-37. doi: 10.1097/QAD.0b013e3283578bfa.

4.

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team.

J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.

5.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

6.

Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children.

Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, Wara D, Read JS, Levin M; IMPAACT P1057 Team.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):189-96. doi: 10.1097/QAI.0b013e3181e46308.

7.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

8.

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.

Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team.

AIDS. 2009 Sep 10;23(14):1893-901. doi: 10.1097/QAD.0b013e32832dc041.

9.

Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era.

Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR 3rd, Oleske J, Williams PL; PACTG 219C Team.

Arch Pediatr Adolesc Med. 2009 Feb;163(2):164-71. doi: 10.1001/archpedi.163.2.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Apr;163(4):364.

10.

Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Patel K, HernĂ¡n MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Jun 1;46(11):1751-60. doi: 10.1086/587900.

11.

Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study.

Williams PL, Van Dyke R, Eagle M, Smith D, Vincent C, Ciupak G, Oleske J, Seage GR 3rd; PACTG 219C Team.

Am J Epidemiol. 2008 Jun 1;167(11):1375-86. doi: 10.1093/aje/kwn072. Epub 2008 Apr 15.

12.

Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J; International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14. doi: 10.1097/QAI.0b013e3181648e16.

13.

Relaxation therapy for hypertension. Comparison of effects with concomitant placebo, diuretic, and beta-blocker.

Jacob RG, Shapiro AP, Reeves RA, Johnsen AM, McDonald RH, Coburn PC.

Arch Intern Med. 1986 Dec;146(12):2335-40.

PMID:
2877644
14.

Increased feeding by rats after subdiabetogenic streptozotocin treatment: a role for insulin in satiety.

Lindberg NO, Coburn PC, Stricker EM.

Behav Neurosci. 1984 Feb;98(1):138-45.

PMID:
6230086
15.

Measurement and modification of the accuracy of determinations of urine glucose concentration.

Epstein LH, Coburn PC, Becker D, Drash A, Siminerio L.

Diabetes Care. 1980 Jul-Aug;3(4):535-6.

PMID:
7460725
16.

Osmoregulatory thirst in rats after lateral preoptic lesions.

Coburn PC, Stricker EM.

J Comp Physiol Psychol. 1978 Apr;92(2):350-61.

PMID:
670458

Supplemental Content

Loading ...
Support Center